Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v16-FR | Version v6-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2024-11-19 | 2024-10-15 |
| Drug Identification Number | 02441608 | 02441608 |
| Brand name | ULTRA-TECHNEKOW V4 | ULTRA-TECHNEKOW V4 |
| Common or Proper name | Sodium Pertechnetate Tc 99m Injection | Sodium Pertechnetate Tc 99m Injection |
| Company Name | CURIUM CANADA INC | CURIUM CANADA INC |
| Ingredients | SODIUM PERTECHNETATE TC-99M | SODIUM PERTECHNETATE TC-99M |
| Strength(s) | 19CI | 19CI |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | 1-19 curies | 1-19 curies |
| ATC code | V09FX | V09FX |
| ATC description | ||
| Reason for shortage | Shortage of an active ingredient. | Shortage of an active ingredient. |
| Anticipated start date | 2024-10-21 | 2024-10-21 |
| Actual start date | ||
| Estimated end date | 2024-11-11 | Unknown |
| Actual end date | 2024-11-11 | |
| Shortage status | Resolved | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | We have been informed by NRG, the operator of the HFR reactor, that a planned inspection of the reactor was recently completed, during which special attention was given to a previously identified deformation in one of the pipes, which is subject to a periodic monitoring program. The mitigation for this deformation was already planned to be executed during the upcoming December 2024 maintenance period. However, during the recent inspection it was determined that the repair must now be completed prior to the start of the next HFR cycle, which was planned for October 10. The current best estimate is that it will take at least a few weeks to finalize. Meanwhile, multiple other reactors that irradiate targets for global Mo 99 production are scheduled to be down for routine and planned maintenance over the coming weeks, and it appears that any meaningful schedule changes will not be possible. Consequently, we expect a significant reduction in global Mo 99 supply over the next several weeks, beginning with the week of October 20. Limited quantities of Mo 99 may be available during certain weeks, but detailed supply projections by day are not yet clear. We understand the significant impact this disruption in supply will have on normal business operations and patient scheduling. We are collaborating with other Mo 99 producers and partners across the industry in an effort to improve the situation and mitigate the impact on supply wherever possible. The situation is fluid, but we expect to be able to provide you with additional details in the coming days and weeks as we learn more. In the meantime, please don’t hesitate to contact a member of our Customer Service team or Sales team with any questions | We have been informed by NRG, the operator of the HFR reactor, that a planned inspection of the reactor was recently completed, during which special attention was given to a previously identified deformation in one of the pipes, which is subject to a periodic monitoring program. The mitigation for this deformation was already planned to be executed during the upcoming December 2024 maintenance period. However, during the recent inspection it was determined that the repair must now be completed prior to the start of the next HFR cycle, which was planned for October 10. While NRG has made progress with testing of a technical solution, additional qualification is required before the work can be completed and the HFR is approved to restart. Accordingly, NRG is not yet able to provide a planned start date. The current best estimate is that it will take at least a few weeks to finalize, which means the start of the October cycle is unlikely. Meanwhile, multiple other reactors that irradiate targets for global Mo 99 production are scheduled to be down for routine and planned maintenance over the coming weeks, and it appears that any meaningful schedule changes will not be possible. Consequently, we expect a significant reduction in global Mo 99 supply over the next several weeks, beginning with the week of October 20. Limited quantities of Mo 99 may be available during certain weeks, but detailed supply projections by day are not yet clear. We understand the significant impact this disruption in supply will have on normal business operations and patient scheduling. We are collaborating with other Mo 99 producers and partners across the industry in an effort to improve the situation and mitigate the impact on supply wherever possible. The situation is fluid, but we expect to be able to provide you with additional details in the coming days and weeks as we learn more. In the meantime, please don’t hesitate to contact a member of our Customer Service team or Sales team with any questions. |
| Health Canada comments |